To the Editor:
Aerosol dissemination of respiratory pathogens may contribute to person-to-person transmission in people with cystic fibrosis (CF) (1). This evolving knowledge of transmission modes has led to an update of the Cystic Fibrosis Foundation Infection and Prevention Control Guidelines recommending people with CF wear surgical masks in communal hospital areas to prevent the spread of CF respiratory pathogens (2). These guidelines recommended the use of surgical masks as source control despite limited evidence for this application.
We recently demonstrated that short-term wear of face masks (10 min total wear) significantly reduces the release of Pseudomonas aeruginosa aerosols during coughing in people with CF (3). These findings are consistent with an earlier study of people with CF that reached the same conclusion after very short-term wear of surgical masks (worn for 21 coughs) (4). These results and a recent editorial to our short-term mask wear study (5) support our current aim to investigate the effectiveness, tolerability, and functionality of face masks as source control after extended wear.
We recruited 25 people with CF and chronic P. aeruginosa infection (6) from the Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia. Ten healthy volunteers were recruited from hospital and research staff to assess mask comfort and mask weight change. All participants performed up to five randomly ordered tests in a validated cough system (7): uncovered cough, coughing with surgical mask worn for 10 minutes, coughing with surgical mask worn for 20 minutes, coughing with surgical mask worn for 40 minutes, and coughing with N95 mask worn for 20 minutes (3, 7). The N95 test was an optional test based on the poor comfort ratings observed in our earlier mask study (3).
The duration of the mask wear tests were selected on the basis of observation of patients moving around communal areas of the hospital described here. Two types of masks were tested: surgical mask (catalog # 47107; Halyard FLUIDSHIELD Level 3 Fog-Free Procedure Mask [∆P < 2.5]) and N95 mask (catalogue #46,827 [small] or 46,727 [regular], Halyard FLUIDSHIELD N95 Particulate Filter Respirator and Surgical Mask). New masks were used for each test. The total wear time of the masks included 1-minute positioning of the participant into the rig, 2 minutes of tidal breathing with air filtered by a high-efficiency particulate air filter, and a 5-minute cough period, followed by another 2 minutes of tidal breathing. Cough aerosol collection, sputum processing, and P. aeruginosa genotyping were performed as previously described (1, 3, 8). All participants rated their comfort levels after each test (3, 9). All masks were weighed before and after each test.
SPSS version 25 was used for statistical analysis. Participants with CF were stratified by the amount of aerosol colony-forming units (CFU) produced during the uncovered cough test: high producer (total count ≥ 10 CFU) or no/low producer (total count < 10 CFU) (3). Categorical variables were examined using Pearson chi-squared test or Fisher’s exact test. Continuous variables were examined using a Student’s t test or Mann-Whitney U test. CFU counts were log transformed, and the paired t test examined changes over time. The McNemar-Bowker test was used to examine comfort scores over time. The Wilcoxon signed-rank test was used to examine the change in mask weight over time.
P. aeruginosa was cultured from the sputum of 25/25 participants with CF and was cultured in cough aerosols during the uncovered cough test of 20/25 participants (Table 1). P. aeruginosa was cultured from cough aerosols of 9/20 participants during any of the surgical mask tests (10-min, 20-min, and 40-min total wear times) and 4/20 participants during the N95 mask test of 20 minutes of total wear. The CFU counts were significantly reduced for the surgical mask tests compared with the uncovered cough test (P < 0.001). Between mask tests, the CFU count remained similar as the duration of surgical mask wear increased, as well as between mask types (Table 1). The P. aeruginosa strain types found in the cough aerosols were genetically indistinguishable from the paired sputum sample of each participant.
Group | Production Level in CF Participants | ||||||
---|---|---|---|---|---|---|---|
Healthy (n = 10) | Cystic Fibrosis (n = 25) | P Value | No/Low (<10 CFU) (n = 14) | High (≥10 CFU) (n = 11) | P Value | ||
Participant characteristics | |||||||
Age, yr, mean (SD) | 37.3 (12.3) | 33.3 (9.0) | 0.29 | 36.7 (9.3) | 28.9 (6.9) | 0.029 | |
Sex, male, n (%) | 6 (60.0) | 15 (60.0) | 1.00 | 9 (64.3) | 6 (54.5) | 0.70 | |
BMI, kg/m2, mean (SD) | 24.6 (3.5) | 22.8 (3.2) | 0.14 | 22.5 (3.7) | 23.1 (2.6) | 0.63 | |
FEV1% predicted, mean (SD) | 92.6 (9.2) | 53.8 (20.8) | <0.001 | 54.2 (23.2) | 53.3 (18.2) | 0.91 | |
Mean P. aeruginosa sputum concentration, ×107 CFU/ml (95% CI)* | n/a | 5.2 (2.1–12.9) | — | 1.9 (0.7–5.7) | 18.3 (4.7–70.9) | 0.008 | |
Participants with P. aeruginosa detected in cough aerosols (total colony counts) | |||||||
Uncovered cough test | |||||||
n (%) | n/a | 20 (80.0) | — | 9 (64.3) | 11 (100.0) | ||
Mean CFU (95% CI)* | 17 (7–43) | 2 (1–4) | 75 (34–165) | <0.001† | |||
Surgical mask tests | |||||||
10 min total wear | |||||||
n (%) | n/a | 9 (36.0) | — | 1 (7.1) | 8 (72.7) | ||
Mean CFU (95% CI)* | 4 (1–10) | 1 | 5 (1–13) | ||||
20 min total wear | |||||||
n (%) | n/a | 9 (36.0) | — | 1 (7.1) | 8 (72.7) | ||
Mean CFU (95% CI)* | 4 (1–10) | 1 | 4 (1–11) | 0.99‡ | |||
40 min total wear | |||||||
n (%) | n/a | 9 (36.0) | — | 1 (7.1) | 8 (72.7) | ||
Mean CFU (95% CI)* | 3 (1–7) | 1 | 4 (1–9) | 0.56§, 0.64|| | |||
N95 mask test¶ | |||||||
20 min total wear (n = 23) | |||||||
n (%) | n/a | 4 (17.4) | — | 0 (0.0)** | 4 (40.0)†† | ||
Mean CFU (95% CI)* | 2 (0–6) | n/a | 2 (0–6) | 0.19‡‡ |
Participants with CF rated surgical masks less comfortable than healthy volunteers for all test durations (surgical mask: 10 min, P = 0.001; 20 min, P = 0.007; 40 min, P = 0.023; N95: 20 min, P = 0.018; Table 2). Participants with CF were more tolerant of surgical mask wear (good comfort) after 10 and 20 minutes of total wear time if they had higher lung function, yet this difference was lost after 40 minutes of surgical mask wear. N95 masks were rated less comfortable in participants with CF and healthy volunteers (Table 2).
Mask Properties | Mask Comfort | Mask Weight Change | |||
---|---|---|---|---|---|
Healthy [n (%)] | Cystic Fibrosis [n (%)] | P Value | All Participants (g) [Median (IQR)] | P Value | |
Uncovered cough comfort level | 1.00 | n/a | n/a | ||
Poor | 0 (0.0%) | 0 (0.0%) | |||
Sufficient | 1 (10.0%) | 2 (8.0%) | |||
Good | 9 (90.0%) | 23 (92.0%) | |||
Coughing wearing a surgical mask: 10 min total wear | 0.001 | 0.01 (0.00–0.02) | n/a | ||
Poor | 1 (10.0%) | 0 (0.0%) | |||
Sufficient | 0 (0.0%) | 15 (60.0%) | |||
Good | 9 (90.0%) | 10 (40.0%) | |||
Coughing wearing a surgical mask: 20 min total wear | 0.007 | 0.01 (0.00–0.02) | 0.73* | ||
Poor | 1 (10.0%) | 1 (4.0%) | |||
Sufficient | 0 (0.0%) | 13 (52.0%) | |||
Good | 9 (90.0%) | 11 (44.0%) | |||
Coughing wearing a surgical mask: 40 min total wear | 0.023 | 0.02 (0.01–0.03) | 0.25†, 0.031‡ | ||
Poor | 1 (10.0%) | 2 (8.0%) | |||
Sufficient | 1 (10.0%) | 15 (60.0%) | |||
Good | 8 (80.0%) | 8 (32.0%) | |||
Coughing wearing N95 mask: 20 min total wear | 0.018 | 0.02 (0.00–0.04) | 0.21§ | ||
Poor | 0 (0.0%) | 11 (47.8%) | |||
Sufficient | 7 (77.8%) | 8 (34.8%) | |||
Good | 2 (22.2%) | 4 (17.4%) |
The change in mask weight for each test ranged from no weight change to a maximum weight change of 0.02 g and was comparable between participants with CF and healthy volunteers (Table 2). There was a minor increase in surgical mask weight (median change, 0.01 g) after 40 minutes compared with 10 minutes of wear (P = 0.031; Table 2). No statistical differences in mask weight change were seen in other time or mask type comparisons (Table 2).
Our study demonstrates that face masks worn for clinically relevant periods are effective at reducing the release of potentially infectious aerosols during coughing in people with CF. These results expand on our earlier observations that demonstrated surgical masks and N95 masks were both effective at reducing the release of infectious cough aerosols when the mask wear was of shorter duration (3). The outcomes of our studies demonstrate that surgical masks are effective and tolerable as source control (3) and support Cystic Fibrosis Foundation recommendations for surgical mask wear to reduce the risk of CF pathogen transmission in the hospital setting (2).
Surgical masks were the preferred mask type for source control in terms of comfort, which is similar to our short-term wear mask study findings (3). Healthy volunteers tolerated the surgical masks better than those with CF, and participants with CF who had higher lung function tolerated surgical masks better. When the comfort of surgical masks was assessed after extended wear in this cohort, a major finding was that the comfort ratings remained unchanged regardless of wear time for both people with and without CF. Therefore, surgical masks are not only effective but are also well tolerated by participants after 40 minutes of total wear.
An accompanying editorial of our recent mask study (3) questioned whether mask dampness may affect the ability of the mask to function as source control after prolonged wear times (5). The CF infection control guidelines indicate that masks being used as source control should be replaced when damp (2), and excessive moisture accumulation was a common reason for surgical mask replacement in people with tuberculosis using surgical masks as source control (10). Our data indicate that although there was evidence of surgical mask moisture accumulation after 40 minutes of total wear (estimated by increased weight), the surgical mask continued to function effectively as source control, mitigating this concern.
There are several limitations to this study. First, the infectious dose of P. aeruginosa is unknown, and therefore the infection risk cannot be determined. Second, participants remained in view of staff while wearing the masks, and this may have modified the extent to which participants interfered with the mask, leading to an incorrect estimation on the mask’s protective effects. Third, participants were seated during the cough testing, and this may have affected the participant’s ability to cough freely. Fourth, although some participants experienced episodes of spontaneous cough during testing, we were unable to differentiate between spontaneous and voluntary cough, and therefore the protective effects of the masks may be overestimated. Fifth, the effectiveness and tolerability of masks is reported in adults only, and these characteristics need to be studied in children. Sixth, our study had a maximum wear time of 40 minutes, and the effectiveness of masks worn for longer periods is unknown. Finally, we did not assess inward protection provided by masks, but this has been highlighted as an understudied field of research (11).
Our study confirms the effectiveness of surgical masks at reducing the release of P. aeruginosa cough aerosols in people with CF and provides evidence of patient tolerability and functionality of these masks as source control after 40 minutes of total wear.
The authors thank Dr. Farhad Salimi for his aerosol support to the study. The authors thank Greg Flohr and staff from the Central Pathology Laboratory (Royal Brisbane and Women’s Hospital), Pathology Queensland for microbiological support to the study. The authors thank the Adult CF Centre team in supporting recruitment to the studies. The authors also thank all the participants in the study for supporting the work.
CF Cough Aerosol Group members: Maureen Peasey, Christine Duplancic, Kay A. Ramsay, Nassib Jabbour, Peter O’Rourke, Claire E. Wainwright, and Peter D. Sly.
1. | Knibbs LD, Johnson GR, Kidd TJ, Cheney J, Grimwood K, Kattenbelt JA, et al. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax 2014;69:740–745. |
2. | Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al.; Cystic Fibrous Foundation; Society for Healthcare Epidemiology of America. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35:S1–S67. |
3. | Wood ME, Stockwell RE, Johnson GR, Ramsay KA, Sherrard LJ, Jabbour N, et al. Face masks and cough etiquette reduce the cough aerosol concentration of Pseudomonas aeruginosa in people with cystic fibrosis. Am J Respir Crit Care Med 2018;197:348–355. |
4. | Vanden Driessche K, Hens N, Tilley P, Quon BS, Chilvers MA, de Groot R, et al. Surgical masks reduce airborne spread of Pseudomonas aeruginosa in colonized patients with cystic fibrosis. Am J Respir Crit Care Med 2015;192:897–899. |
5. | Simmonds NJ, Bush A. The man in the paper mask: one (Mask) for all and all for . . . cystic fibrosis? Am J Respir Crit Care Med 2018;197:281–283. |
6. | Ramsay KA, Sandhu H, Geake JB, Ballard E, O’Rourke P, Wainwright CE, et al. The changing prevalence of pulmonary infection in adults with cystic fibrosis: a longitudinal analysis. J Cyst Fibros 2017;16:70–77. |
7. | Johnson GR, Knibbs LD, Kidd TJ, Wainwright CE, Wood ME, Ramsay KA, et al. A novel method and its application to measuring pathogen decay in bioaerosols from patients with respiratory disease. PLoS One 2016;11:e0158763. |
8. | Syrmis MW, Kidd TJ, Moser RJ, Ramsay KA, Gibson KM, Anuj S, et al. A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis. BMC Infect Dis 2014;14:307. |
9. | Gregoretti C, Confalonieri M, Navalesi P, Squadrone V, Frigerio P, Beltrame F, et al. Evaluation of patient skin breakdown and comfort with a new face mask for non-invasive ventilation: a multi-center study. Intensive Care Med 2002;28:278–284. |
10. | Dharmadhikari AS, Mphahlele M, Stoltz A, Venter K, Mathebula R, Masotla T, et al. Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med 2012;185:1104–1109. |
11. | MacIntyre CR, Chughtai AA. Facemasks for the prevention of infection in healthcare and community settings. BMJ 2015;350:h694. |
The project was funded by Cystic Fibrosis Foundation Therapeutics USA (BELL14AO). T.J.K. acknowledges National Health and Medical Research Council Early Career (GNT10884488) and ERS-EU RESPIRE2 Marie Sklodowska-Curie Postdoctoral Research (#4571-2013) Fellowship support. L.D.K. acknowledges a National Health and Medical Research Council Early Career Fellowship (APP1036620). R.E.S. acknowledges The Prince Charles Hospital Foundation and Advance Queensland Ph.D. Scholarships.
Author Contributions: R.E.S., L.J.S., T.J.K., G.R.J., L.D.K., L.M., and S.C.B. conceived of and designed the experiment; T.J.K., L.M., and S.C.B. led the funding applications with other members of the CF Cough Aerosol Group (Claire E. Wainwright and Peter D. Sly); M.E.W. and S.C.B. recruited the study participants; R.E.S. and C.H. conducted the cough studies; G.R.J. acquired the aerosol data; R.E.S. performed microbiological analysis; E.L.B. led the data analysis; R.E.S. and S.C.B. provide overall responsibility for the data and wrote the manuscript, with input from all coauthors; and CF Cough Aerosol Group members Maureen Peasey, Christine Duplancic, Kay A. Ramsay, Nassib Jabbour, Peter O’Rourke, Claire E. Wainwright, and Peter D. Sly provided support to the study, including analysis and/or microbiology expertise and/or clinical supervision.
Originally Published in Press as DOI: 10.1164/rccm.201805-0823LE on July 20, 2018
Author disclosures are available with the text of this letter at www.atsjournals.org.